StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

Analysts at StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock opened at $0.06 on Friday. Syros Pharmaceuticals has a 1 year low of $0.06 and a 1 year high of $6.93. The stock has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.85. The firm has a market capitalization of $1.65 million, a PE ratio of -0.02 and a beta of 1.31.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SYRS. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the third quarter worth $34,000. Two Sigma Securities LLC acquired a new position in Syros Pharmaceuticals in the 4th quarter valued at $25,000. Finally, Exome Asset Management LLC raised its holdings in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after acquiring an additional 139,400 shares during the period. Institutional investors and hedge funds own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.